for the Period Ended 31 March 2024
Directors report | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 March 2024
Principal activities of the company
Directors
The director shown below has held office during the whole of the period from
1 April 2023
to
31 March 2024
The director shown below has held office during the period of
1 April 2023
to
13 December 2023
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
As at
Notes | 2024 | 2023 | |
---|---|---|---|
|
£ |
£ |
|
Fixed assets | |||
Intangible assets: | 3 |
|
|
Tangible assets: | 4 |
|
|
Investments: |
|
|
|
Total fixed assets: |
|
|
|
Current assets | |||
Stocks: |
|
|
|
Debtors: | 5 |
|
|
Cash at bank and in hand: |
|
|
|
Investments: |
|
|
|
Total current assets: |
|
|
|
Prepayments and accrued income: |
|
|
|
Creditors: amounts falling due within one year: | 6 |
(
|
(
|
Net current assets (liabilities): |
|
|
|
Total assets less current liabilities: |
|
|
|
Creditors: amounts falling due after more than one year: |
|
|
|
Provision for liabilities: |
(
|
(
|
|
Accruals and deferred income: |
|
|
|
Total net assets (liabilities): |
|
|
|
Members' funds | |||
Profit and loss account: |
|
|
|
Total members' funds: |
|
|
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 March 2024
Basis of measurement and preparation
Turnover policy
Tangible fixed assets depreciation policy
Intangible fixed assets amortisation policy
Other accounting policies
for the Period Ended 31 March 2024
2024 | 2023 | |
---|---|---|
Average number of employees during the period |
|
|
for the Period Ended 31 March 2024
Goodwill | Other | Total | |
---|---|---|---|
Cost | £ | £ | £ |
At 1 April 2023 |
|
|
|
Additions |
|
|
|
Disposals |
|
|
|
Revaluations |
|
|
|
Transfers |
|
|
|
At 31 March 2024 |
|
|
|
Amortisation | |||
At 1 April 2023 |
|
|
|
Charge for year |
|
|
|
On disposals |
|
|
|
Other adjustments |
|
|
|
At 31 March 2024 |
|
|
|
Net book value | |||
At 31 March 2024 |
|
|
|
At 31 March 2023 |
|
|
for the Period Ended 31 March 2024
Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
---|---|---|---|---|---|---|
Cost | £ | £ | £ | £ | £ | £ |
At 1 April 2023 |
|
|
||||
Additions |
|
|
||||
Disposals | ||||||
Revaluations | ||||||
Transfers | ||||||
At 31 March 2024 |
|
|
||||
Depreciation | ||||||
At 1 April 2023 |
|
|
||||
Charge for year |
|
|
||||
On disposals | ||||||
Other adjustments | ||||||
At 31 March 2024 |
|
|
||||
Net book value | ||||||
At 31 March 2024 |
|
|
||||
At 31 March 2023 |
|
|
for the Period Ended 31 March 2024
2024 | 2023 | |
---|---|---|
£ | £ | |
Trade debtors |
|
|
Prepayments and accrued income |
|
|
Total |
|
|
for the Period Ended 31 March 2024
2024 | 2023 | |
---|---|---|
£ | £ | |
Taxation and social security |
|
|
Other creditors |
|
|
Total |
|
|
for the Period Ended 31 March 2024
Name of director receiving advance or credit: |
|
Description of the transaction: | |
|
|
£ | |
---|---|
Balance at 31 March 2023 |
|
Advances or credits made: |
|
Advances or credits repaid: |
|
Balance at 31 March 2024 |
|
During the financial year of Mar 2023 - Mar 2024, Black Pharma benefited the community in the following ways: Mentorship Programme Delivered our 2023/24 Mentorship Programme, sponsored by a pharmaceutical employer. Black Pharma’s Mentorship Programme is designed to provide 6 months of dedicated 1:1 support to mentees to enhance their professional development. The 2023/24 programme included 100 participants (46 mentees and 54 mentors), with 70% rating the programme 5 stars. Collectively, participants contributed 10,000 hours of mentee-to-mentor engagement. Career Fairs Hosted both in-person and virtual Black Pharma stands at career fairs at Brunel University, University of Bristol, Loughborough University, and Hertfordshire University, where our Brand Ambassadors shared valuable information about career opportunities within the pharmaceutical industry. Reach Society Career Fair: Hosted a Black Pharma stand at the 2023 Reach Society Career Fair, a social enterprise event encouraging, motivating, and inspiring young people to realise their potential. Events Black Pharma organised a range of impactful in-person and virtual events, including: Networking Events: Hosted two in-person networking events with 102 attendees, providing opportunities for our community members to connect and share experiences. Educational and Community Events: Facilitated virtual “fireside chats” discussing key diversity and inclusion topics relevant to the pharmaceutical industry. Delivered a virtual CV and Cover Letter Workshop for students and early career professionals. Annual Summit: Hosted our first-ever Annual Summit, “Together We Can: Amplifying Diverse Voices,” attended by 167 delegates and four diversity partners. The summit featured panel discussions, networking opportunities, and shared insights that empowered beneficiaries to thrive.
Black Pharma’s stakeholders include our members, followers, customers, sponsors, and educational institutions (i.e., universities). We engage with our stakeholders to get feedback on the services we provide and suggestions on how we can better serve the community in the following ways: Black Pharma has engaged with various stakeholders to ensure a holistic approach to community service. Our primary stakeholders include our members, followers, customers, sponsors, and educational institutions, particularly universities. To foster open communication and collaboration, Black Pharma has employed several consultation methods throughout the reporting period: Member Surveys: Regular post programme and/or event surveys are conducted among our members to gather their opinions on the quality of our services, their needs, and areas for improvement. Sponsor Meetings: We maintain an ongoing dialogue with our sponsors to understand their expectations, align our goals and ensure our initiatives align with their corporate social responsibility objectives. Educational Institution Collaborations: Regular meetings and collaborations with universities help us stay connected with academic institutions. These interactions enable us to align our programmes with educational needs and identify opportunities for mentorship and skill development. During the reporting period, the following actions were taken: Service Enhancements: Based on member and customer feedback, we have implemented enhancements to our services, including updates to our programmes, website, and stakeholders support processes. Community Outreach Programmes: Stakeholder suggestions, specifically from our pharmaceutical employer, inspired the creation of a new community outreach programmes ‘Cultivate’ career programme in partnership with a pharmaceutical employer. Cultivate was a 4-week long online programme for students, graduates and early career professionals, providing foundational industry knowledge and training for a successful career in industry’ Sponsorship Programme Improvements: Feedback from sponsors informed adjustments to our sponsorship mentoring programme, ensuring that they align more closely with the values and goals of our corporate partners. We introduced the Black Pharma’s Mentorship Programme which was designed to provide 6 months of dedicated 1:1 support to mentees to support their professional development and allowed our sponsors pharmaceutical employers to provide mentors to supplement the industry knowledge and skills component of the programme. Educational Initiatives: Collaboration with educational institutions has led to the development of tailored educational initiatives, including student led workshops by Black Pharma’s Brand Ambassadors and peer-to-peer in-person and social networking.
The total amount paid or receivable by Director Amponsah Adjalo Ms J in respect of qualifying services was £3,750 There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director’s loss of office, which require to be disclosed
No transfer of assets other than for full consideration
This report was approved by the board of directors on
21 November 2024
And signed on behalf of the board by:
Name: S Oyesola
Status: Director